Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friederike Schumann

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
MMW Fortschritte Der Medizin|June 26, 2020
[HIV and dyslipidemia - reasons and therapy]Tim Hollstein, Friederike Schumann, Ursula Kassner
MMW Fortschritte Der Medizin|February 11, 2022
[LAL-D - underdiagnosed, but important]Ursula Kassner, Linus Haberbosch, Friederike Schumann
Sensors (Basel, Switzerland)|March 11, 2023
Online Learning for Wearable EEG-Based Emotion ClassificationSidratul Moontaha, Franziska Elisabeth Friederike Schumann, Bert Arnrich
Herz|April 22, 2022
[Statin intolerance and statin-associated muscular pain]Paulina Elena Stürzebecher, Friederike Schumann, Ursula Kassner, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 10, 2020
PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 WeeksTim Hollstein, Ursula Kassner, Thomas Grenkowitz, et al.
Journal of Clinical Lipidology|June 22, 2024
Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevationFriederike Schumann, Ursula Kassner, Dominik Spira, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|February 3, 2026
Long-term efficiency of pallidal DBS and the role of Levodopa treatment in DYT-GNAL and 18p deletion syndrome associated dystonia: an observational study and review of literatureJohanna Reimer, Friederike Schumann, Katja Lohmann, et al.
Journal of Lipid Research|October 17, 2018
The interrelations between PCSK9 metabolism and cholesterol synthesis and absorptionGünther Silbernagel, Lars K Steiner, Tim Hollstein, et al.
Cardiovascular Research|July 27, 2021
The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitorsValentin Blanchard, Kévin Chemello, Tim Hollstein, et al.
Vascular Pharmacology|September 28, 2020
Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular riskCécile Ingueneau, Tim Hollstein, Thomas Grenkowitz, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
MMW Fortschritte Der Medizin|June 26, 2020
[HIV and dyslipidemia - reasons and therapy]Tim Hollstein, Friederike Schumann, Ursula Kassner
MMW Fortschritte Der Medizin|February 11, 2022
[LAL-D - underdiagnosed, but important]Ursula Kassner, Linus Haberbosch, Friederike Schumann
Sensors (Basel, Switzerland)|March 11, 2023
Online Learning for Wearable EEG-Based Emotion ClassificationSidratul Moontaha, Franziska Elisabeth Friederike Schumann, Bert Arnrich
Herz|April 22, 2022
[Statin intolerance and statin-associated muscular pain]Paulina Elena Stürzebecher, Friederike Schumann, Ursula Kassner, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 10, 2020
PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 WeeksTim Hollstein, Ursula Kassner, Thomas Grenkowitz, et al.
Journal of Clinical Lipidology|June 22, 2024
Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevationFriederike Schumann, Ursula Kassner, Dominik Spira, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|February 3, 2026
Long-term efficiency of pallidal DBS and the role of Levodopa treatment in DYT-GNAL and 18p deletion syndrome associated dystonia: an observational study and review of literatureJohanna Reimer, Friederike Schumann, Katja Lohmann, et al.
Journal of Lipid Research|October 17, 2018
The interrelations between PCSK9 metabolism and cholesterol synthesis and absorptionGünther Silbernagel, Lars K Steiner, Tim Hollstein, et al.
Cardiovascular Research|July 27, 2021
The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitorsValentin Blanchard, Kévin Chemello, Tim Hollstein, et al.
Vascular Pharmacology|September 28, 2020
Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular riskCécile Ingueneau, Tim Hollstein, Thomas Grenkowitz, et al.
Pageof 2